Navigation Links
ACORN CRO Continues Growth in Strong Third Quarter
Date:11/10/2008

Oncology Focused Contract Research Organization Exceeds Expectations

MEMPHIS, Tenn., Nov. 10 /PRNewswire/ -- ACORN CRO, a Contract Research Organization exclusively focused on oncology, announced today that its third quarter had once again exceeded projections as the company continues to experience banner growth. "The industry has responded favorably to ACORN's ability to consistently exceed client expectations, and we are ahead of projections in both number of projects, patients accrued, and revenue generated. Our strong, active relationship with community oncology and its physicians along with our proprietary technology provide sponsors with a combination for success," remarked Steve Coplon, ACORN CEO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081110/CLM032LOGO )

ACORN CRO currently provides services for both specific cancer types and supportive care studies with additional projects ready to launch in the near future. Positioned for continued growth in 2009, ACORN CRO has expanded its staff and capabilities. ACORN CRO's experienced team provides sponsors with Project and Site Management; Data Management via Guardian EDC(TM); Statistics and Statistical Programming; and Medical and Scientific Writing.

Founded in community oncology and grounded with the most stringent scientific disciplines, ACORN CRO seamlessly incorporates the best of both worlds. "Though ACORN operates with a strong business model focused on operational success, scientific excellence guides our organization," according to Dr. Lee Schwartzberg, President and Chief Medical Director. Nationally recognized for his commitment to research at the community level, Dr. Schwartzberg co-founded Accelerated Community Oncology Research Network (ACORN), enabling oncologists nationwide to provide their patients the most promising research initiatives.

ACORN CRO evolved in response to sponsor requests for value-driven quality solutions and accelerated patient accruals. With a team approach, ACORN CRO lends itself to highly efficient and accurate trial operations. Close working relationships with community oncology practices enable prompt accruals.

"The trajectory of ACORN CRO for 2009 portends the most successful year for our company," stated Coplon. "We look forward to seeing sponsors at various meetings to showcase our abilities."

For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

ACORN CRO

ACORN CRO is a full-service, oncology-focused contract research organization, providing value-driven, quality solutions to the pharmaceutical and biotech industry and offering unparalleled customer service in monitoring; clinical data management; statistical analysis; medical writing and project management. ACORN CRO delivers insights from key oncology opinion leaders and accelerates the research process through advanced levels of efficiency.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055 x1312

dcoble@sosacorn.com


'/>"/>
SOURCE ACORN CRO
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
2. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
3. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
4. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
5. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
9. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):